Sei Investments Co. Buys 91,103 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Sei Investments Co. lifted its stake in Twist Bioscience Co. (NASDAQ:TWST) by 40.8% during the second quarter, Holdings Channel reports. The fund owned 314,658 shares of the company’s stock after acquiring an additional 91,103 shares during the quarter. Sei Investments Co.’s holdings in Twist Bioscience were worth $15,507,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after buying an additional 284,884 shares during the last quarter. Norges Bank acquired a new position in Twist Bioscience during the 4th quarter worth $10,766,000. UBS Group AG lifted its position in Twist Bioscience by 106.4% during the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock worth $7,868,000 after acquiring an additional 110,036 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Twist Bioscience by 1.3% during the fourth quarter. Franklin Resources Inc. now owns 173,924 shares of the company’s stock valued at $6,411,000 after acquiring an additional 2,263 shares during the period. Finally, Evoke Wealth LLC acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at about $572,000.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. TD Cowen upped their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Guggenheim assumed coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now directly owns 504,732 shares in the company, valued at approximately $24,227,136. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Emily M. Leproust sold 1,114 shares of the business’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares of the company’s stock, valued at approximately $24,227,136. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Patrick John Finn sold 2,207 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total value of $124,960.34. Following the transaction, the chief operating officer now owns 171,212 shares of the company’s stock, valued at $9,694,023.44. The disclosure for this sale can be found here. Insiders sold a total of 17,386 shares of company stock worth $770,915 over the last quarter. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

Shares of TWST stock opened at $47.08 on Friday. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90. The stock has a fifty day moving average price of $46.46 and a 200 day moving average price of $43.24. The stock has a market cap of $2.76 billion, a P/E ratio of -14.01 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience’s revenue was up 27.7% on a year-over-year basis. During the same period in the previous year, the business posted ($1.01) earnings per share. Equities research analysts anticipate that Twist Bioscience Co. will post -3.13 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.